BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Relapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 91
- Registration Number
- NCT03206918
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Conditions
- Refractory Mantle Cell LymphomaRelapsed Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 86
- Registration Number
- NCT03206970
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 44
- Registration Number
- NCT03189524
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Institute of Hematology and Hospital of Blood Disease, Tianjin, Tianjin, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 139
- Registration Number
- NCT03150810
- Locations
- 🇺🇸
Start Midwest, Grand Rapids, Michigan, United States
🇺🇸Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸Montefiore Medical Park At Eastchester Einstein Campus, Bronx, New York, United States
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 41
- Registration Number
- NCT03145064
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Soochow University Branch Shizi, Suzhou, Jiangsu, China
🇨🇳Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 201
- Registration Number
- NCT03053440
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 75
- Registration Number
- NCT02795182
- Locations
- 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇦🇺Concord Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Hobart Hospital, Hobart, Tasmania, Australia
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 229
- Registration Number
- NCT02660034
- Locations
- 🇺🇸
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 131
- Registration Number
- NCT02610361
- Locations
- 🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺North Coast Cancer Institute, Macquarie, New South Wales, Australia
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
- Conditions
- B-cell Lymphoid Malignancies
- Interventions
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 119
- Registration Number
- NCT02569476
- Locations
- 🇺🇸
Florida Cancer Specialists Fort Myers, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States